BRIEF published on 12/19/2025 at 12:05, 8 months 13 days ago Biotest AG annonce l'approbation par la FDA du Fesilty™ de Grifols Biotest AG Marché Américain Approbation De La FDA Grifols Thérapie Au Fibrinogène
BRIEF published on 12/19/2025 at 12:05, 8 months 13 days ago Biotest AG Announces FDA Approval of Grifols' Fesilty™ FDA Approval Biotest AG U.S. Market Grifols Fibrinogen Therapy
PRESS RELEASE published on 12/19/2025 at 12:00, 8 months 13 days ago Biotest announces US FDA approval of Grifols’ Fesilty™ (fibrinogen, human-chmt) Biotest AG announces US FDA approval of Grifols’ Fesilty™ (fibrinogen, human-chmt) for acute bleeding episodes in patients with fibrinogen deficiency Biotest AG Fibrinogen Grifols US FDA Approval Fesilty
BRIEF published on 11/13/2025 at 10:12, 9 months 19 days ago Biotest obtient l'autorisation de mise sur le marché de Prufibry® en Allemagne Biotest AG Essais Cliniques Marché Allemand Approbation Prufibry® Déficit En Fibrinogène
BRIEF published on 11/13/2025 at 10:12, 9 months 19 days ago Biotest Obtains Approval for Prufibry® in Germany Clinical Trials Biotest AG German Market Prufibry® Approval Fibrinogen Deficiency
PRESS RELEASE published on 11/13/2025 at 10:07, 9 months 19 days ago Biotest obtains approval for new human fibrinogen Prufibry® in Germany Biotest AG obtains approval in Germany for new human fibrinogen Prufibry®, expanding intensive care and coagulation factor portfolio with a life-saving therapy for congenital and acquired fibrinogen deficiency Germany Biotest AG Approval Human Fibrinogen Prufibry
BRIEF published on 11/07/2025 at 15:24, 9 months 24 days ago Biotest AG convoque une assemblée générale extraordinaire à la demande de Grifols Assemblée Générale Extraordinaire Grifols SA Société En Commandite Par Actions Biotest AG Changement De Forme Juridique
BRIEF published on 11/07/2025 at 15:24, 9 months 24 days ago Biotest AG Schedules Extraordinary General Meeting at Grifols' Request Grifols S.A. Extraordinary General Meeting Biotest AG Legal Form Change Partnership Limited By Shares
PRESS RELEASE published on 11/07/2025 at 15:19, 9 months 24 days ago Biotest AG: Extraordinary general meeting convened again at the request of Grifols S.A. Biotest AG convenes an extraordinary general meeting at the request of Grifols S.A. to discuss changing its legal form to a partnership limited by shares (KGaA) on 17 December 2025 Grifols S.A. Extraordinary General Meeting Biotest AG Legal Form Change Partnership Limited By Shares
BRIEF published on 10/23/2025 at 13:21, 10 months 9 days ago Biotest AG Cancels Extraordinary General Meeting Grifols S.A. Extraordinary General Meeting Legal Form Change Corporate Restructuring Biotest AG News
Published on 09/01/2026 at 23:05, 11 hours 9 minutes ago Aton Announces US$30M Credit Facility with OU Moonrider
Published on 09/01/2026 at 22:30, 11 hours 44 minutes ago Algo Grande Copper Closes Oversubscribed Private Placement for $4.786 Million
Published on 09/01/2026 at 22:15, 11 hours 59 minutes ago NuRAN Wireless Announces Plans to Voluntarily Delist from the Canadian Securities Exchange
Published on 09/01/2026 at 16:10, 18 hours 4 minutes ago Sparton Signs Definitive Morrison Silver Mine Option and Joint Venture Agreement with Glen Eagle; Appoints Vice President, Corporate Development
Published on 09/02/2026 at 10:05, 9 minutes ago Thunes Champions Ethical Global Payments with its 2026 United Nations Global Compact Commitment
Published on 09/02/2026 at 10:05, 9 minutes ago PANASONIC PIONEERS GLOBAL SHUTTER TECHNOLOGY WITH AW-UE200 & AW-UER200 PTZ SERIES
Published on 09/02/2026 at 10:05, 9 minutes ago CIGRE 2026: Building power grids for a new age of electrification
Published on 09/02/2026 at 10:05, 9 minutes ago BTL Establishes New Laser Division and Introduces EXOLASE ONE® - The World's First Fused Erbium Laser
Published on 09/02/2026 at 07:43, 2 hours 30 minutes ago Accor launches an offering of bonds convertible into new shares and/or exchangeable for existing shares (OCEANEs) due 2032 for a nominal amount of €380 million and a concurrent partial repurchase offer with respect to its outstanding OCEANEs due 2027 by
Published on 09/02/2026 at 07:43, 2 hours 30 minutes ago Accor lance une émission d’obligations à option de conversion en actions nouvelles et/ou d’échange en actions existantes (OCEANEs) à échéance 2032 pour un montant nominal de 380 millions d’euros et une offre concomitante de rachat partiel de s
Published on 09/01/2026 at 19:00, 15 hours 14 minutes ago Covivio - Information on total number of voting rights and share capital
Published on 09/01/2026 at 19:00, 15 hours 14 minutes ago Covivio - Informations relatives au nombre total de droits de vote et d’actions composant le capital social
Published on 09/01/2026 at 18:18, 15 hours 56 minutes ago TF1 - Déclaration mensuelle des actions et droits de vote - Août 2026
